REPLIMUNE GROUP INC (REPL)       17.27  +0.65 (+3.91%)

17.27  +0.65 (+3.91%)

US76029N1063 - Common Stock - After market: 17.27 0 (0%)

REPLIMUNE GROUP INC17.27

NASDAQ:REPL (9/30/2022, 7:00:02 PM)+0.65 (+3.91%)

After market: 17.27 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/bmo Earnings (Next) 11-02 2022-11-02
Ins Owners 18.68% Inst Owners 82.25%
Market Cap 851.53M Shares 49.31M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.25
IPO 07-20 2018-07-20

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

REPL Daily chart

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 206 full-time employees. The company went IPO on 2018-07-20. The firm is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The firm's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The firm's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathway activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Company Info

REPLIMUNE GROUP INC

500 Unicorn Park Dr

Woburn MASSACHUSETTS 01801

P: 17812229600.0

CEO: Philip Astley-Sparke

Employees: 206

Website: https://www.replimune.com/

REPL News

News Image2 months ago - Replimune Group IncReplimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous...

News Image2 months ago - Replimune Group IncReplimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image3 months ago - Market News VideoNotable Friday Option Activity: ENTG, REPL, ROKUNews Image4 months ago - Replimune Group IncReplimune Announces the Departure of Jason Rhodes from its Board of Directors

WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image4 months ago - Replimune Group IncReplimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab),...

News Image5 months ago - Replimune Group IncReplimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data...

REPL Twits

Here you can normally see the latest stock twits on REPL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example